Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24427305 | 0.81 | MEN1 (0.38) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL24427705 | 0.81 | MEN1 (0.38) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL10367117 | 0.81 | MEN1 (0.38) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL24427304 | 0.77 | MEN1 (0.48) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL24427550 | 0.69 | CYP2A6 (0.35) | — | |
| SCHEMBL6796193 | 0.67 | MAOB (0.45) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL31552720 | 0.67 | KMT2A (0.55) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL10433870 | 0.66 | — | — | |
| SCHEMBL1031679 | 0.65 | NOTUM (0.48) | — | |
| SCHEMBL30686938 | 0.65 | NOTUM (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171461-A1 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4482839-A2 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | Geode Therapeutics Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-119110800-A | Modulators of interferon gene stimulating factor (STING), compositions and methods | 健道生物医药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2023158862-A2 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158862-A2 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| US-6825199-B2 | 7-Substituted quinazolin-2,4-diones useful as antibacterial agents | WARNER-LAMBERT COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1028950-B1 | 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | DOMAGALA JOHN MICHAEL (US) | 2002-08-22 | — | — | US | disclosed |
| US-6331538-B1 | TREATMENT OF BACTERIAL INFECTION | WARNER-LAMBERT COMPANY | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171461-A1 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | STING1, IRF3, CGAS | MEN1 1561/4885ALDH1A1 4836/4885GAA 960/4885 |
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | NQO2, TOP1, TOP2A | MEN1 2437/4885ALDH1A1 3064/4885GAA 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.